Document:

Exhibit 4.1

 

 

THIS NOTE HAS NOT BEEN REGISTERED UNDER
THE FEDERAL OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR HYPOTHECATED IN ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT UNDER SUCH LAWS AS MAY BE APPLICABLE OR, AN OPINION OF COUNSEL THAT AN EXEMPTION FROM SUCH APPLICABLE LAWS EXIST.

 

PROMISSORY NOTE

 

	Principal Amount:   $250,000.00	Issuance Date: January 31, 2017

Maturity Date: March 2, 2017

 

FOR VALUE RECEIVED,
Authentidate Holding Corp., a Delaware corporation (the “Borrower”), with its principal offices located at 2225
Centennial Drive, Gainesville, GA 30504 hereby promises to pay to HANIF A. ROSHAN (the “Holder”) at such address
as the Holder designates in writing to the Borrower, the principal sum of TWO HUNDRED AND FIFTY THOUSAND DOLLARS ($250,000.00)
(the “Principal Amount”), on the Maturity Date stated above. This Note is a direct obligation of the Borrower
and ranks subordinate to the rights of the holders of outstanding debt securities previously issued by Borrower.

 

1.        Interest
on this Note shall be computed at the rate of 12% per annum, payable in arrears on the Maturity Date, at which time all accrued
and unpaid interest shall be immediately due and payable. All computations of interest payable hereunder shall be on the basis
of a 360-day year and actual days elapsed in the period for which such interest is payable. Accrued interest on the outstanding
principal amount shall be due and payable on the Maturity Date in cash. Payments of all amounts due hereunder shall be made in
lawful money of the United States.

 

2.       Payment
of the Principal Amount of this Note, and interest thereon, shall be made upon the surrender of this Note to the Borrower, at its
chief executive office (or such other office within the United States as shall be designated by the Borrower to the Holder hereof)
(the “Designated Office”), in such coin or currency of the United States of America as at the time of payment
shall be legal tender for the payment of public and private debts. If the Maturity Date shall be a Saturday or a Sunday or
shall be a legal holiday in the State of Georgia, then such action may be taken or such right may be exercised on the
next succeeding day not a legal holiday.

 

3.       Exchange
Right.  

 

(a)          For as long
the Note remains outstanding, the Holder shall have the right, in accordance with the terms hereof, to exchange the principal amount
of the Note (and unpaid interest thereon) into the securities of the Borrower (the “New Securities”) sold in
the Next Financing (defined below). The Holder may exchange all, but not less than all, of the principal amount of the Note, and
any accrued and unpaid interest thereon, for the New Securities in the Next Financing upon the same price and other terms and conditions
as pertains to the Next Financing and shall be required to execute such agreements pertaining to the Next Financing as the Borrower
and the other investors participating in the Next Financing shall execute. In calculating the number of New Securities to be issued
to the Holder, such number shall be rounded down to the nearest whole number. The Borrower shall not issue any fractional New Securities
under any circumstances, but shall pay to the Holder any cash amounts in respect of the value of any fractional New Securities
that may have been issuable in the absence of the aforementioned prohibition. As used herein, the term “Next Financing”
shall mean the closing of a sale of equity or debt securities by the Borrower, or series of closings, as part of the same transaction,
of equity or debt securities within a period of three months, wherein the Borrower receives cash proceeds in the gross amount of
at least $1,000,000, excluding any transaction that is an Exempt Issuance, as defined below (the “Next Financing”).
The Holder may exercise this right at any time and from time to time prior to repayment of this Note in accordance with the provisions
of paragraph 3(b) of this Note.

 

    1

     

    

 

(b)          Mechanics.
To exchange the Note into the Next Financing, upon no less than two (2) business days’ written notice by the Holder to the
Borrower, the Holder shall send by facsimile (or otherwise deliver) a notification of its intent to exercise the exchange right
herein. The Holder shall surrender or cause to be surrendered the Note as soon as practicable thereafter to the Borrower,
and pay any transfer taxes or other applicable taxes or duties, if required.  The Borrower shall not be obligated to
issue New Securities unless either the Note is delivered to the Borrower as provided above, or the Holder notifies the Borrower
that the Note has been lost, stolen or destroyed and delivers to the Borrower an affidavit of loss in a form reasonably acceptable
to the Borrower. As promptly as practicable on or after the closing of the Next Financing, the Borrower shall issue and deliver
to the Holder such number of securities of the Borrower issuable to it in the Next Financing. The Holder is not entitled to any
rights of a holder of New Securities until the Note has been surrendered and exchanged (or an appropriate affidavit of loss has
been accepted) for such New Securities in the Next Financing and the closing of such Next Financing has occurred. Upon such event,
the rights of the Holder of the Note as the Holder hereof shall cease, and the person or persons entitled to receive the New Securities
shall be deemed to be a holder of record of such New Securities.

 

(c)          As used
herein, the term “Exempt Issuance” means the issuance of (i) any securities of the Borrower to employees, officers,
or directors of the Borrower or other eligible person pursuant to any stock or option plan duly adopted for such purpose, by a
majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors
established for such purpose (for purposes of clarity, the issuance of shares of Common Stock upon exercise of options or vesting
of restricted stock units granted pursuant to such an equity compensation plan subsequent to the date hereof shall also be an Exempt
Issuance), (ii) securities upon the exercise, exchange or conversion of any securities of the Borrower issued and outstanding as
of the Issuance Date of this Note (including shares of common stock that the Borrower may issue pursuant to the presently outstanding
shares of preferred stock in lieu of cash dividends thereon), (iii) securities issued pursuant to mergers, acquisitions or strategic
transactions approved by a majority of the disinterested directors of the Borrower, provided that any such issuance shall only
be to a person (or to the equityholders of a person) which is, itself or through its subsidiaries, an operating company or an owner
of an asset in a business synergistic with the business of the Borrower and shall provide to the Borrower additional benefits in
addition to the investment of funds (for purposes of clarity, an Exempt Issuance shall not include a transaction in which the Borrower
is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities),
(iv) shares of Common Stock (or securities convertible into or exercisable or exchangeable for shares of Common Stock) which may
be issued to consultants, vendors, lessors, distributors or similar persons, to the Borrower as consideration for services or assets
provided to the Borrower (and the shares of Common Stock which may be issued upon exercise or conversion of convertible securities
issued to the class persons specified in this clause), and (v) shares of Common Stock or other securities issued in connection
with any stock split, stock dividend or recapitalization of the Borrower.

 

4.       Events
of Default.

 

(a)          For purposes of this Note, an “Event of Default” shall consist of any of the following events:

 

(1)          The
Borrower shall fail to pay any portion of the Principal Amount of this Note when the same becomes due and payable, whether at the
Maturity Date or at any accelerated date of maturity or at any other date fixed for payment, and such default continues for 10
days or more.

 

    2

     

    

 

(2)          The
Borrower shall voluntarily commence any case, proceeding or other action under any existing or future law of any jurisdiction,
domestic or foreign, relating to bankruptcy, insolvency, or relief of debtors, seeking to have an order for relief entered with
respect to it, or seeking to adjudicate it as bankrupt or insolvent, or seeking other relief with respect to its debts; or a court
shall enter an order for relief or any such adjudication or appointment, which case, proceeding or action or order, adjudication,
or appointment, as the case may be, remains undismissed, undischarged or unbonded for a period of 60 days, then, or any time thereafter
during the continuance of any of such events.

 

(3)          A
final judgment for money damages or order for the payment of money damages in excess of One Hundred and Fifty Thousand Dollars
($250,000) (exclusive of amounts covered by insurance) shall be entered against the Borrower, which has not been vacated or stayed
within 15 days of entry.

 

(4)          Any
material representation or warranty of the Borrower herein or in the Purchase Agreement shall prove to have been false in any material
respect upon the date when made.

 

(5)          The occurrence
of a default (after giving effect to any grace periods or rights to cure held by the Borrower) under any material indebtedness
of the Borrower resulting from other than the failure to timely pay interest or principal of such indebtedness which results in
the acceleration of the maturity of such indebtedness.

 

(6)          The Borrower
shall liquidate, dissolve, terminate or suspend its business operations.

 

(b)          Acceleration
of Payment. If an Event of Default (other than an Event of Default specified in Section 4(a)(2) hereof with respect to
the Borrower) occurs and is continuing, the Holder, by written notice to the Borrower, may declare due and payable the principal
amount of this Note, plus accrued and unpaid interest thereon. Upon a declaration of acceleration, such principal shall be immediately
due and payable. If an Event of Default specified in Section 4(a)(2) occurs with respect to the Borrower, the principal of
this Note shall become and be immediately due and payable, without any declaration or other act on the part of the Holder. Further,
upon an Event of Default, from such date of the Event of Default, Holder shall be entitled, and this Note shall bear interest at
the rate of 2.00% per month until such Event of Default is cured. For purposes of this note, a “month” shall mean a
30-day period. Upon the payment in full of the amounts due under this Note, the Holder shall promptly surrender this Note to or
as directed by the Borrower.

 

(c)           Collections.
If an Event of Default with respect to this Note occurs and is continuing, the Holder may pursue any available remedy by proceeding
at law or in equity to collect the defaulted payment or to enforce the performance of any provision of this Note. Notwithstanding
any other provision in this Note, the Holder of this Note shall have the right, which is absolute and unconditional, to receive
payment of the principal in respect of the Notes held by the Holder, on or after the final Maturity Date, or to bring suit for
the enforcement of any such payment on or after such date, and such rights shall not be impaired or affected adversely without
the consent of the Holder.

 

(d)           No
Exclusive Right or Remedy. Except as otherwise provided herein, no right or remedy conferred in this Note upon the Holder is
intended to be exclusive of any other right or remedy, and every right and remedy shall, to the extent permitted by law, be cumulative
and in addition to every other right and remedy given hereunder or hereafter existing at law or in equity or otherwise.  The
assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment
of any other appropriate right or remedy. No delay or omission of the Holder of this Note to exercise any right or remedy accruing
upon any Event of Default shall impair any such right or remedy or constitute a waiver of any such Event of Default or any acquiescence
therein.  Every right and remedy given by this Section 4 or by law to the Holder may be exercised from time to time,
and as often as may be deemed expedient, by the Holder.

 

    3

     

    

 

5.       Transferability;
Loss and Replacement.

 

(a)          This Note has not been registered under the Securities Act, or the securities laws of any state or other jurisdiction.  Neither
this Note nor any interest or participation herein may be reoffered, sold, assigned, transferred, pledged, encumbered or otherwise
disposed of (a “Transfer”) in the absence of registration under the Securities Act and any applicable state
securities laws, or unless (i) such transaction is exempt from, or not subject to, registration under the Securities Act or
the securities laws of any state or other jurisdiction and (ii) is made in compliance with applicable federal and state statutory
resale restrictions, if any.  The Holder by its acceptance of this Note agrees that it shall not offer, sell, assign,
transfer, pledge, encumber or otherwise dispose of this Note or any portion thereof or interest therein other than in a minimum
denomination of $50,000 principal amount (or any integral multiple of $10,000 in excess thereof) and then (other than with respect
to a Transfer pursuant to a registration statement that is effective at the time of such Transfer) only (a) to the Borrower,
(b) to an affiliate of the Holder, (c) to a Person it reasonably believes to be an “accredited investor”
within the meaning of Rule 501(a) under the Securities Act, or (d) pursuant to a transaction in compliance with
Rule 144 or Rule 144A under the Securities Act, and in the case of (b), (c) and (d) above in which the transferor
furnishes the Borrower with such certifications, legal opinions or other information as the Borrower may reasonably request to
confirm that such transfer is being made pursuant to an exemption from, or in a transaction not subject to, the registration requirements
of the Securities Act as applicable. 

 

(b)          By
receipt and acceptance of this Note, Holder and any permitted transferee represents and warrants to the Borrower that (i) it is
an “accredited investor” as defined in Rule 501(a) under the Securities Act; (ii) either alone or together with its
representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating
the merits and risks of the prospective investment in the Note, and has so evaluated the merits and risks of such investment;
(iii) is able to bear the economic risk of an investment in the Note and, at the present time, is able to afford a complete loss
of such investment; (iv) understands that the Note will be characterized as “restricted securities” under U.S. federal
securities laws and have not been and are not being registered under the Securities Act or any state securities laws, must be
held indefinitely and may not be offered for sale, sold, assigned or transferred except in accordance therewith and (vii) it has
reviewed the Borrower’s filings with the Securities and Exchange Commission and has been afforded (A) the opportunity
to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Borrower concerning the
terms and conditions of this Note and the merits and risks of the prospective investment in the Note and the Borrower generally
and, (B) it has access to information about the Borrower and its subsidiaries and their respective financial condition, results
of operations, business, properties, management and prospects sufficient to enable it to evaluate the terms and conditions of
this Note and the merits and risks of the prospective investment in the Borrower.

 

    4

     

    

 

(c)          The Transfer of this Note is registrable on the books of the Borrower upon surrender of this Note for registration of Transfer
at the Borrower’s designated office, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory
to the Borrower duly executed by, the Holder hereof or such Holder’s attorney duly authorized in writing, and thereupon one
or more new Notes, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee
or transferees.  Prior to due presentation of this Note for registration of Transfer, the Borrower and any agent of the
Borrower may treat the Person in whose name this Note is registered as the owner thereof for all purposes, whether or not this
Note be overdue, and neither the Borrower nor any such agent shall be affected by notice to the contrary. Upon presentation of
this Note for registration of Transfer at the Borrower’s designated office accompanied by (i) certification by the transferor
that such Transfer is in compliance with the terms hereof and (ii) by a written instrument of Transfer in a form approved
by the Borrower executed by the Holder, in person or by the Holder’s attorney thereunto duly authorized in writing, and including
the name, address and telephone and fax numbers of the transferee and name of the contact person of the transferee, such Note shall
be transferred on the Note Register, and a new Note of like tenor and bearing the same legends shall be issued in the name of the
transferee and sent to the transferee at the address and c/o the contact person so indicated.  Transfers and exchanges
of Notes shall be subject to such additional restrictions as are set forth in the legends on the Notes and to such additional reasonable
regulations as may be prescribed by the Borrower as specified herein.  Successive registrations of Transfers as aforesaid
may be made from time to time as desired, and each such registration shall be noted on the Note register. No Transfer shall be
allowed except to an “accredited investor” as defined under the rules and regulations of the Securities and Exchange
Commission.

 

(d)          Upon receipt by the Borrower of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of
this Note, and in the case of loss, theft or destruction, receipt of indemnity reasonably satisfactory to the Borrower and upon
surrender and cancellation of this Note, if mutilated, the Borrower will deliver a new Note of like tenor and dated as of such
cancellation, in lieu of such Note.

 

6.       Miscellaneous.

 

(a)          This
Note constitutes the entire agreement between the parties relating to the subject matter hereof and supersedes any and all previous
agreements and understandings, oral or written, relating to the subject matter hereof. Neither this Note nor any term hereof may
be amended or waived orally or in writing, except that any term of this Note may be amended and the observance of any term of this
Note may be waived (either generally or in a particular instance and either retroactively or prospectively), and such amendment
or waiver shall be applicable upon the approval of the Borrower and the Holder.

 

(b)          This
Note and the rights and obligations of the Holder and of the undersigned shall be governed and construed in accordance with the
laws of the State of Georgia.

 

(c)          Upon
the occurrence and during the continuance of an Event of Default under this Note, the Borrower shall, upon demand, pay to the Holder
the amount of any and all reasonable costs and expenses (including reasonable attorneys’ fees) that Holder may incur in connection
with the enforcement or collection of this Note.

 

(d)          No
failure or delay on the part of the Holders hereof in the exercise of any power, right or privilege hereunder shall operate as
a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise
thereof or of any other right, power or privilege. All rights and remedies existing hereunder are cumulative to, and not exclusive
of, any rights or remedies.

 

(e)          The
Borrower hereby, to the fullest extent permitted by applicable law, waives presentment, demand, notice (including without limitation
notice of default (except as otherwise specifically set forth herein), notice of protest, notice of intention to accelerate maturity,
notice of acceleration of maturity and notice of nonpayment or dishonor), protest and all other demands and notices in connection
with delivery, acceptance, performance, default, acceleration or enforcement of or under this Note, and the bringing of suit and
diligence in taking any action to collect amounts owing hereunder or in proceeding against any of the rights and properties securing
payment hereof, and is directly and primarily liable for the amount of all sums owing or to be owing hereon. No extension of the
time for the payment of this Note made by agreement with any person now or hereafter liable for the payment of this Note shall
operate to release, discharge, modify, change or affect the original liability of the Borrower under this Note.

    5

     

    

 

(f)          To
the extent that Holder receives any payment on account of any of Borrower’s obligations under this Note, and any such payment(s)
or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, subordinate and/or required
to be repaid to a trustee, receiver or any other person or entity under any bankruptcy act, state or federal law, common law or
equitable cause, then, to the extent of such payment(s) received, the Borrower’s obligations or part thereof intended to
be satisfied shall be revived and continue in full force and effect, as if such payment(s) had not been received by the Holder
and applied on account of Borrower’s obligations.

 

(g)          Section headings
used herein are for convenience of reference only, are not part of this Note and shall not affect the construction of, or be taken
into consideration in interpreting, this Note.

 

(h)          If
any provision of this Note is invalid, illegal or unenforceable, the balance of this Note shall remain in effect, and if any provision
is inapplicable to any person or circumstance, it shall nevertheless remain applicable to all other persons and circumstances.
If the Borrower is at any time required or obligated to pay interest hereunder at a rate that would be in excess of a statutory
or legally permitted rate, then the rate of interest shall be deemed to be immediately reduced to such maximum rate and the interest
payable shall be computed at such maximum rate and any prior interest payments in excess of such maximum rate shall be applied
and shall be deemed to have been payments in reduction of the principal balance of this Note. 

 

(i)          All
notices, offers, acceptance and any other acts under this Note (except payment) shall be in writing, and shall be sufficiently
given if delivered to the addressees in person, by FedEx or similar receipted next business day delivery, or by facsimile or email
delivery followed by overnight next business day delivery to the Borrower at the address set forth above (or such other address
as the Borrower may by notice to the Holder may designate from time to time) and to the Holder at the address set forth above (or
such other address as the Holder by notice to the Borrower may designate from time to time). Time shall be counted to, or from,
as the case may be, the date of delivery.

 

 

[Signature Page Follows]

 

    6

     

    

 

IN WITNESS WHEREOF,
the Borrower has caused this Note to be executed as of the Issuance Date.

 

BORROWER:

 

AUTHENTIDATE HOLDING
CORP.

 

 

By: ___________________________

Name: Marc
A. Horowitz

Title:   Chairman of the Audit Committee

 

 

    7Exhibit 10.1

 

 

 

271 Waverly Oaks Road, Suite 108

Waltham, MA 02452

 

February 1, 2017

 

Sarah Romano, CPA

6 Anthony Road

Newton, MA 02460

Dear Sarah:

 

EyeGate Pharmaceuticals, Inc. (the “Company”)
is pleased to offer you a promotion to the Company’s Interim Chief Financial Officer effective as of the date of this letter
(the “Effective Date”). This letter is intended to summarize some of the terms of your employment, and amends
and restates in its entirety the letter agreement between you and the Company dated as of July 20, 2016. We refer you to the policies,
plans and practices of the Company for more details on the terms and conditions of your employment.

 

Your employment is considered “at will”; both you
and the Company have the right to terminate your employment at any time for any reason. This letter does not constitute, and shall
not be construed as, creating a contract or promise of employment for any set period of time.

 

You will report to Stephen From, President and Chief Executive
Officer of the Company, and will be responsible for all tasks attendant to the role of Interim Chief Financial Officer of an R&D
stage specialty pharmaceutical company, including but not limited to managing the financial statements, SEC reporting, audit of
the financial statements, internal controls and Sarbanes-Oxley compliance, accounting function management including budgets and
forecasts and financial strategy of the Company, and duties assigned to you by the CEO from time to time.

 

Your starting base salary in your new position will be $6,153.85
every two weeks (which annualizes to $160,000), less applicable withholdings and deductions. In addition, you will be eligible
to earn an incentive bonus/commission based on goals set by the Company after the Effective Date, with an annual target of up to
twenty percent (20%) of your base salary.

 

In addition to the foregoing, you will be eligible to participate
in fringe benefit plans as may be generally available to other Company employees. Policies applicable to other employees of the
Company shall also be applicable to you. Initially, this will include eligibility to participate in the Company’s group health
plan, reimbursement for Company approved travel (in accordance with the Company’s expense reimbursement policies), and accrual
of up to twenty (20) days per year of paid vacation time (accrued and useable in accordance with the Company’s vacation policies).
Vacation days stop accruing after reaching the maximum allowable accrual for the year, after which time no vacation time will be
accrued until used.

 

     

     

    

 

Employment with the Company is contingent on verification of
eligibility to work. Due to the Immigration Reform and Control Act of 1986, all employees hired after November 6, 1986, must provide
verification of employment eligibility prior to commencement of employment. Your employment is also contingent on your execution
of the Company’s standard Employee Nondisclosure, Noncompetition, Nonsolicitation and Inventions Agreement.

 

Additionally, you represent that you are not subject to and
will not be subject to any agreements, restriction or obligations, including any noncompetition agreements or restrictions or any
nondisclosure or confidentiality agreement or restrictions, which prevent you from performing (or in any other way adversely impact
your ability to perform), your employment duties on behalf of the Company. Whether or not you are bound by the terms of any such
agreements, you agree that during your employment with the Company, you will not disclose or use, or induce anyone at the Company
to use, any confidential, proprietary or trade secret information or material belonging to any former employer or other person
or entity.

 

The terms set forth herein shall not be modified except pursuant
to a written agreement signed by both parties. This letter is governed by Massachusetts law.

 

[Remainder of page left blank intentionally]

 

 

    2 

     

    

 

We look forward to your contributions towards the growth of
the Company.

 

Sincerely,

 

EyeGate Pharmaceuticals, Inc.

 

 

	/s/ Stephen From	 
	By: Stephen From	 
	Its:  President and Chief Executive Officer	 

 

Receipt Acknowledged and Terms Agreed To:

 

 

	/s/ Sarah Romano	 	February 1, 2017	 
	Sarah Romano, CPA	 	Date	 

 

    3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}]]